Comparative Analysis Indicates Benefits from OncoSil

News

Comparative Analysis Indicates Benefits from OncoSil

Melbourne, Australia – 26 January 2024: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), is pleased to announce the results of the first comparative analysis in a matched cohort of patients indicating that adding OncoSil™ to chemotherapy provides significant survival, local disease control and resection benefits in patients with unresectable locally advanced pancreatic cancer (LAPC), compared to chemotherapy.

The retrospective, investigator-initiated propensity-score weighted landmark analysis indicated a relative mean survival advantage of a further 3.7 months survival in 50 patients receiving OncoSil™ plus chemotherapy compared to 54 patients receiving standard-of-care chemotherapy, with or without additional external radiotherapy. There was also a 3.7 months relative mean survival benefit for local progression-free survival (PFS) and a 2.5 months relative mean survival benefit for distant PFS. Significantly more patients receiving OncoSil™ were downstaged (31.4% vs. 13.6%, respectively) or underwent surgical resection (28.6% vs. 12.1%, respectively), compared with chemotherapy.

The analysis was performed by investigators at the Royal Adelaide Hospital, South Australia, and Waikato Hospital, New Zealand, and presented at the Australian Gastroenterology Week (AGW 24) in Adelaide by Dr Amanda Lim, an advanced endoscopy fellow at Beth Israel Deaconess Medical Centre in Boston, MA, USA, and an academic researcher from RAH. Dr Lim was honoured with the prestigious Young Investigators Award at the AGW 24 meeting “in recognition of the most meritorious research contribution to the scientific program by a Young Investigator in either Basic and Clinical Research” and delivered a 15-minute presentation titled:

Clinical Research: Combined phosphorus-32 implantation and chemotherapy: A comparison with standard therapy using a propensity-score weighted landmark analysis and an assessment of its impact on vascularity in locally advanced pancreatic cancer.

The propensity-score weighted landmark analysis marks a significant milestone for OncoSil Medical, as the presentation provided the first study of adding OncoSil™ to chemotherapy compared to a matched cohort of patients with unresectable LAPC receiving standard-of-care chemotherapy. The presentation also covered the impact of OncoSil™ plus chemotherapy on the vascularity of the treated pancreatic tumours.

Reference
Lim, A. H., Nitchingham, D., Bednarz, J., Bills, M., Lanka, L., Allen, B., Tan, A., Joshi, R., Hsieh, W., Crouch, B., Zobel, J., Thomson, J.-E., Neo, E., Safaeian, R., Tse, E., Rayner, C., Ruszkiewicz, A., Wong, J., Singhal, N., … Nguyen, N. (2024). Combined phosphorus-32 implantation and chemotherapy: A comparison with standard therapy using a propensity-score weighted landmark analysis and an assessment of its impact on vascularity in locally advanced pancreatic cancer. Journal of Gastroenterology and Hepatology, 39, 39.
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.16697